Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accumulated Expenses (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Accumulated Expenses for 6 consecutive years, with $38.0 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Expenses changed N/A to $38.0 million in Q4 2024 year-over-year; TTM through Nov 2024 was $38.0 million, a N/A change, with the full-year FY2024 number at $38.0 million, changed N/A from a year prior.
  • Accumulated Expenses was $38.0 million for Q4 2024 at Nurix Therapeutics, up from $21.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $38.0 million in Q4 2024 to a low of $5.0 million in Q2 2021.
  • A 5-year average of $18.4 million and a median of $19.7 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 295.79% in 2022, then grew 11.72% in 2023.
  • Nurix Therapeutics' Accumulated Expenses stood at $5.7 million in 2020, then skyrocketed by 154.13% to $14.5 million in 2021, then skyrocketed by 54.15% to $22.4 million in 2022, then decreased by 2.32% to $21.9 million in 2023, then skyrocketed by 73.43% to $38.0 million in 2024.
  • Per Business Quant, the three most recent readings for NRIX's Accumulated Expenses are $38.0 million (Q4 2024), $21.9 million (Q3 2023), and $22.4 million (Q4 2022).